Metraipolis › archive › dc_bc20600f1def

Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy — Europe PMC PMID:41377239

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41377239
DOI
10.1097/ms9.0000000000004164
License (as archived)
solo-consultazione
Archived
2026-11-08T23:48:15.065Z
SHA-256 of the archived text
3d60e67859e437283c712c360bc72e85ffdfe0ffa4399eec95d1261156541826
Stable URL of this page
https://metraipolis.com/documento/dc_bc20600f1def

How to cite

Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy — Europe PMC PMID:41377239 — Europe PMC (en), https://europepmc.org/article/MED/41377239 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bc20600f1def (Metraipolis archive dc_bc20600f1def, sha256 3d60e67859e437283c712c360bc72e85ffdfe0ffa4399eec95d1261156541826)
BibTeX
@misc{dcbc20600f1def,
  title = {Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy — Europe PMC PMID:41377239},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41377239},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bc20600f1def; sha256 3d60e67859e437283c712c360bc72e85ffdfe0ffa4399eec95d1261156541826},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41377239. Agents can read the archived copy with the MCP tool read_document.